

# Feasibility study of e-cigarettes in periodontitis

<b>Submission date</b> 19/09/2016	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
<b>Registration date</b> 27/09/2016	<b>Overall study status</b> Completed	<input checked="" type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
<b>Last Edited</b> 10/10/2023	<b>Condition category</b> Oral Health	<input type="checkbox"/> Individual participant data

## Plain English summary of protocol

### Background and study aims

Tobacco smoking is well known to have negative effects on oral health. In particular, smoking dramatically increases the risk of developing gum (periodontal) disease, which can lead to tooth loss. Dentists therefore play a role in helping patients to stop smoking and provide stop smoking advice to their patients. Electronic cigarettes (e-cigarettes) are increasing in popularity and there is growing evidence they may be an effective way to help people give up smoking. With several million users of e-cigarettes in the UK it is important that dentists understand the role they may play in helping their patients to stop smoking. However, there is no research to show their usefulness within the dental setting and any potential effects for oral health, particularly periodontal health. The aim of this study is to investigate the effect of e-cigarettes on periodontal health, in order to find out whether a large scale study would be possible.

### Who can participate?

Smokers over 18 years old who have been diagnosed with severe, long-term gum disease.

### What does the study involve?

Participants are randomly allocated to one of two groups. Participants in the first group receive usual stop smoking advice from the dentist. Participants in the second group receive usual stop smoking advice from the dentist as well as an e-cigarette starter kit and brief training on how to use it. Participants in both groups then receive normal periodontal therapies delivered over several appointments. A sample of the participants is also asked to attend 1-3 additional visits so they can be interviewed about their experiences in the study. The amount of participants taking part is recorded in order to find out whether a larger scale study would be possible.

### What are the possible benefits and risks of participating?

As participants in this study receive periodontal therapies, they may see significant improvements to their gum health. Participants also benefit from receiving help with quitting smoking, which will hopefully help reduce smoking levels which is beneficial for general and oral health. There are no known risks involved with participating.

### Where is the study run from?

Newcastle Dental Hospital (UK)

When is the study starting and how long is it expected to run for?  
December 2015 to November 2018

Who is funding the study?  
National Institute for Health Research (UK)

Who is the main contact?  
Dr Richard Holliday  
richard.holliday@newcastle.ac.uk

## Contact information

**Type(s)**  
Scientific

**Contact name**  
Dr Richard Holliday

**ORCID ID**  
<http://orcid.org/0000-0002-9072-8083>

**Contact details**  
D4.016  
Newcastle Dental Hospital  
Richardson Road  
Newcastle Upon Tyne  
United Kingdom  
NE2 4AZ  
+44 191 233 6161 (ext 26812)  
richard.holliday@newcastle.ac.uk

## Additional identifiers

**EudraCT/CTIS number**  
Nil known

**IRAS number**

**ClinicalTrials.gov number**  
Nil known

**Secondary identifying numbers**  
CPMS 32034

## Study information

**Scientific Title**  
A mixed methods feasibility study of electronic cigarette use by patients with periodontitis

**Study objectives**

The aim of this study is to assess the viability of delivering and studying an e-cigarette intervention prior to a definitive study.

### **Ethics approval required**

Old ethics approval format

### **Ethics approval(s)**

North East - Tyne & Wear South Research Ethics Committee, 03/08/2016, ref: 16/NE/0219

### **Study design**

Randomized; Interventional; Design type: Treatment, Prevention, Complex Intervention

### **Primary study design**

Interventional

### **Secondary study design**

Randomised controlled trial

### **Study setting(s)**

Other

### **Study type(s)**

Treatment

### **Participant information sheet**

Not available in web format, please use the contact details to request a patient information sheet

### **Health condition(s) or problem(s) studied**

Specialty: Oral and dental health, Primary sub-specialty: Oral and dental public health; UKCRC code/ Disease: Oral and Gastrointestinal/ Diseases of oral cavity, salivary glands and jaws

### **Interventions**

Following assessment of eligibility and completion of informed consent participants will be randomised to one of two groups, in a 1:1 ratio using random permuted blocks. The randomisation allocation schedule will be generated by a statistician with no other involvement in the study to achieve concealment of allocation.

Control group: Participants receive standard stop smoking advice from the dentist. This involves the '3 A's': Ask, Advise, Act technique and the option of a referral to Newcastle stop smoking services.

Intervention group: Participants receive the same standard stop smoking advice from the dentist as the control group but are also given an e-cigarette starter kit and given brief training on its use.

For all participants, follow up involves normal periodontal therapies delivered over several appointments.

A sample of the participants will be asked to attend 1-3 additional visits for qualitative interviews about their experiences in the study.

## **Intervention Type**

Other

### **Primary outcome measure**

Feasibility outcomes:

1. Eligibility rate will be measured by examining screening records at the end of the study
2. Patients' willingness to enter the trial will be measured by established by examining screening records at the end of the study and by the qualitative interviews
3. Recruitment rate will be measured by recording the number of eligible participant who consent to participate in the study by 12 months
4. Participation biases will be established by examining the screening/ recruitment data at the end of the study
5. Retention rate will be established by recording the number of participants who remain in the study until the end of follow up
6. Randomised group contamination rates (i.e. the extent of cross-over between the two arms of the trial) will be established by recording the e-cigarette use of all participants over the duration of the study
7. Periodontal Inflamed Surface Area [PISA] will be measured at baseline, 3-months and 6-months
8. Periodontal Epithelial Surface Area [PESA] will be measured at baseline, 3-months and 6-months
9. Pocket Probing Depths [PPDs]) will be measured at baseline, 3-months and 6-months
10. Distribution of microbiome is assessed using subgingival plaque samples at baseline, 3-months and 6-months
11. Distributional properties of the inflammatory biomarkers is assessed using subgingival plaque samples at baseline, 3-months and 6-months
12. Participant compliance with e-cigarette use is measured by self-reported feedback, weekly data collection and qualitative interviews
13. Tobacco smoking and e-cigarette usage is measured by self-reported feedback, weekly data collection and biochemical measures
14. Participant behaviour regarding the use of the e-cigarette is established by qualitative interviews
15. A Qualitative Process Evaluation will establish the views of participants on the provision of e-cigarettes and to finalise the exact characteristics of an e-cigarette intervention for the future definitive study for this patient group

### **Secondary outcome measures**

There are no secondary outcome measures

### **Overall study start date**

01/12/2015

### **Completion date**

30/11/2018

## **Eligibility**

### **Key inclusion criteria**

1. Aged over 18 years old
2. Smoker of burnt tobacco ( $\geq 10$  factory-made cigarettes/day or 7 g [0.25 oz] loose tobacco or 14

hand-rolled cigarettes/day)

3. Not currently using an EC, or not used one for more than two days in the last 30 days
4. Be willing and able to come to the Dental Clinical Research facility in the Newcastle Dental Hospital for the required study visits
5. Minimum of 20 natural teeth (excluding third molars)
6. Diagnosed with severe chronic periodontal disease having interproximal pocket probing depths (PPDs) of  $\geq 5$  mm at  $\geq 8$  teeth and BOP scores  $\geq 30\%$
7. Have read, understood and signed an informed consent form

### **Participant type(s)**

Patient

### **Age group**

Adult

### **Lower age limit**

18 Years

### **Sex**

Both

### **Target number of participants**

Planned Sample Size: 80; UK Sample Size: 80

### **Total final enrolment**

80

### **Key exclusion criteria**

1. Having used an e-cigarette for more than 2 days in the last 30 days
2. Infectious or systemic diseases that may be unduly affected by participation in this study
3. Haemodynamically unstable patients hospitalised with severe arrhythmias, myocardial infarction, cerebrovascular accident
4. Suffering from Pheochromocytoma
5. Suffering from uncontrolled hyperthyroidism
6. Liver or Kidney problems
7. Chronic Obstructive Pulmonary Disease
8. Patients taking the medication Adenosine
9. Lack of capacity to be able to consent to the research project and/or inability to follow study instructions
10. Participation in a dental research study within the previous 20 days
11. Pregnant by medical history, or nursing
12. Received any non-surgical periodontal therapy other than a routine scale and polish in the last 6 months
13. Currently undergoing or requiring extensive dental, orthodontic or implant treatment, or treatment for peri-implantitis

Eligibility Criteria requiring further discussions with individual participants:

1. Asthma (Severity needs to be assessed. Patient made aware that NRT better than smoking but best to use NRT as a short term stop smoking treatment).
2. Long term throat disease (Severity needs to be assessed. NRT use may exacerbate symptoms)
3. Stomach Ulcer, duodenal ulcer, irritation or inflammation of the stomach or throat (NRT may

exacerbate symptoms)

4. Patient with diabetes mellitus will be advised to monitor their blood glucose more closely when initiating treatment. They will be advised to discuss this with their doctor or diabetic nurse.

5. Patients taking medications metabolised by CYP 1A2 and that have a narrow therapeutic window can be affected by stopping smoking. Patients taking theophylline, clozapine and ropinirole will be asked to see their doctor to discuss changing the dose prior to starting the quit attempt.

**Date of first enrolment**

20/09/2016

**Date of final enrolment**

19/09/2017

## **Locations**

**Countries of recruitment**

England

United Kingdom

**Study participating centre**

**Newcastle Dental Hospital**

Richardson Road

Newcastle upon Tyne

United Kingdom

NE2 4AZ

## **Sponsor information**

**Organisation**

Newcastle Upon Tyne Hospitals NHS Foundation Trust

**Sponsor details**

Freeman Hospital

Freeman Road

High Heaton

Newcastle Upon Tyne

England

United Kingdom

NE7 7DN

**Sponsor type**

Hospital/treatment centre

**ROR**

## Funder(s)

### Funder type

Government

### Funder Name

National Institute for Health Research

### Alternative Name(s)

National Institute for Health Research, NIHR Research, NIHRresearch, NIHR - National Institute for Health Research, NIHR (The National Institute for Health and Care Research), NIHR

### Funding Body Type

Government organisation

### Funding Body Subtype

National government

### Location

United Kingdom

## Results and Publications

### Publication and dissemination plan

The findings of this research will be disseminated locally (at departmental meetings), and nationally and internationally via presentations at research conferences. The results of the research will be written up for submission for publication in peer reviewed national and international journals. It is likely that the findings of this research will be of interest to the general public, and Newcastle University has an established press office for communicating findings of research to the press in an appropriate format.

### Intention to publish date

30/11/2019

### Individual participant data (IPD) sharing plan

The datasets generated and/or analysed during the current study during this study will be included in the subsequent results publication

### IPD sharing plan summary

Other

### Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
-------------	---------	--------------	------------	----------------	-----------------

<a href="#">Results article</a>	results	04/06/2019	10/06/2019	Yes	No
<a href="#">HRA research summary</a>			28/06/2023	No	No
<a href="#">Statistical Analysis Plan</a>		04/06/2019	10/10/2023	No	No